title: Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines.
abstract: Invariant natural killer T (iNKT) cells have the capacity to amplify adaptive immune responses by licensing antigen-presenting cells. A simple vaccine consisting of whole tumor cells pulsed with an iNKT-cell agonist efficiently delivers antigens plus adjuvants to endogenous dendritic cells and has potential for clinical applications.
authors.affiliation: Malaghan Institute of Medical Research; Wellington, New Zealand ; School of Biological Sciences; Victoria University of Wellington; Wellington, New Zealand.
authors.forename: Martin K
authors.initials: MK
authors.lastname: Hunn
authors.forename: Ian F
authors.initials: IF
authors.lastname: Hermans
keywords: NKT cell; cancer vaccine; dendritic cell; glioblastoma multiforme; glioma; α-galactosylceramide